INVO Fertility, Inc. (Nasdaq: IVF) announced its financial results for the third quarter ended September 30, 2026, in a Form 8-K filed on November 16, 2026. The company reported a 26% increase in total revenue to approximately $2.22 million for the quarter, driven by a 28% rise in consolidated clinic revenue to $2.21 million.

Key financial metrics for the third quarter of 2026 include a net loss of $2.1 million, an improvement from a net loss of $3.4 million in the prior year. The company also reported a loss from operations of $1.5 million, narrowing from $1.6 million in the prior year. Consolidated Adjusted EBITDA was reported as a loss of $(1.0) million, compared to $(0.9) million in the prior year.

On a segment basis, the Fertility Clinic Services segment generated $292,114 in Clinic-Level Adjusted EBITDA for the seventh consecutive quarter. This figure was supported by organic growth at the Wisconsin and Atlanta clinics and contributions from the Indiana and Birmingham clinics, which were acquired earlier in 2026. However, the Birmingham clinic transition resulted in a negative impact of approximately $193,000 on the quarter's clinic-level contribution due to anticipated revenue disruption and increased costs associated with recruiting a new physician.

The company’s balance sheet showed improvement, with cash totaling approximately $3.7 million as of September 30, 2026. Current liabilities were reported at approximately $4.5 million, a reduction from $10.3 million at December 31, 2025. Assets increased by $5.3 million, and liabilities decreased by $5.5 million, resulting in net equity of $18.0 million, or $15.09 per share.

Management noted that the company has implemented new tools to reduce time spent on documentation and administrative work across its practices. The company also attended the American Society for Reproductive Medicine Scientific Congress & Expo in October 2026, resulting in further expansion of potential acquisition opportunities.